Applied Microbiology and Biotechnology

, Volume 97, Issue 3, pp 1231–1239

Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface

Authors

  • Pedro Ribelles
    • Commensal and Probiotics–Host Interactions LaboratoryINRA
    • AgroParisTech
    • Area de MicrobiologíaInstituto Universitario de Biotecnología, Universidad de Oviedo
  • Bouasria Benbouziane
    • Commensal and Probiotics–Host Interactions LaboratoryINRA
    • AgroParisTech
    • Laboratory of Beneficial Microorganisms, Functional Foods and Health, Department of BiotechnologyUniversity of Mostaganem
  • Philippe Langella
    • Commensal and Probiotics–Host Interactions LaboratoryINRA
    • AgroParisTech
  • Juan E. Suárez
    • Instituto de Productos Lácteos de Asturias (CSIC)
    • Area de MicrobiologíaInstituto Universitario de Biotecnología, Universidad de Oviedo
    • Commensal and Probiotics–Host Interactions LaboratoryINRA
    • AgroParisTech
  • Ali Riazi
    • Laboratory of Beneficial Microorganisms, Functional Foods and Health, Department of BiotechnologyUniversity of Mostaganem
Applied genetics and molecular biotechnology

DOI: 10.1007/s00253-012-4575-1

Cite this article as:
Ribelles, P., Benbouziane, B., Langella, P. et al. Appl Microbiol Biotechnol (2013) 97: 1231. doi:10.1007/s00253-012-4575-1

Abstract

Human papillomavirus (HPV) is the causative agent of cervical cancer (CxCa) and the most commonly sexually transmitted pathogen worldwide. HPV type 16 (HPV-16) E7 oncoprotein is constitutively produced in CxCa and considered as a good antigen candidate for the development of new therapeutic CxCa vaccines. Here, we report the use of non-genetically modified, E7-expressing lactic acid bacteria (LAB) by using the cell-binding domain from Lactobacillus casei A2 phage lysin as a cell wall anchor. The versatility of this system was validated by investigating E7 stability at the surface of Lactococcus lactis and L. casei, two major species of LAB. Moreover, we demonstrated the successful use of these LAB displaying E7 antigen as a mucosal live vaccine in mice. Altogether, these results show the feasibility of using non-genetically modified LAB for low-cost mucosal immunotherapy against HPV-related CxCa in humans.

Keywords

Mucosal vaccinesLactococcus lactisLactobacillus caseiLactic acid bacteriaA2 phage lysinCell wall anchorE7HPV-16

Copyright information

© Springer-Verlag Berlin Heidelberg 2012